Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (September 2021)
43 slides from Windtree Therapeutics's investor presentation, Sep 20, 2021
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics Company Overview September 20, 2021 WINDTREE THERAPEUTICS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company
Slide 3: Windtree Therapeutics Highlights
Windtree Therapeutics Highlights GS Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) GF Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths:
Slide 4: Windtree Therapeutics Pipeline
Windtree Therapeutics Pipeline elimina [re | Phases | phase | phase |Next nttestone | Istaroxime (Acute Heart Failure) Potential for Istaroxime Breakthrough _—_ (Early Cardiogenic Shock) designation Oral SERCA2a Activators (Chronic HF; potentially HFpEF) KL4 Surfactant —COVID 19 (COVID 19 Pilot; Pos
Slide 5: Strategy for Value Creation
Strategy for Value Creation Planned Milestones Q2 Q3 Q4 Ql Q2 Q3 Q4 Istaroxime Early Cardiogenic Shock Study Data ---~ Istaroxime Data, then Acute Heart Failure Study EOP2 Miginto (transition to Phase 3)** iret artnerin KL4 Surfactant nin COVID-19 Lung Injury Treatment / Data Timing TBO: AEROSURF AE
Slide 6: Istaroxime
Istaroxime Dual Mechanism SERCA2aq Activator Acute Heart Failure and
Slide 7: Heart Failure — Large, Growing Market But Underserved
Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing Vv 6M U.S., 20M+ worldwide patients Vv #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) In-patien
Slide 8: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need = Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g. “dry out”) with i.v. diuretics * Improve cardiac function and peripheral/organ perfusion * Achieve stable, fully compensated clinical
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart =~ = Inhibition of the sodium- Stimulation of SERCA2a activity enhances calcium reuptake resulting in ; . potassium pumpandeffectson [StarOxXime improvemen
Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary
Istaroxime AHF Phase 2a & 2b Studies —- Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients SB & © n=120 Dosing= 6 hour Phase 25 ADHF Patients 0.5, 1, 1.5 ug/kg/min Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/kg/min Infusion (dyspnea plus need
Slide 11: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio and Stroke Volume istaroxime 0.5 pg/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 20 20 10 10 00 0 10 10 e 2.20 $20 é é 30 yy 30 a Fe’ 3, 50 50 Infusion period Infusion period * j * ‘ a e * pyvalue = 0.029 a? Paes See 10 70 Bacine
Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo ———— a 9 = Systolic & Blood 3 Pressure = 2 (SBP) é Infusion period 7 erat t 3 : = 011, ** p-values $0006 geal or agro godt gaa ero gyro a po
Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 pg/kg/min vs. placebo a5 * pvalue=0.014 Change in Heart Rate (bpm) Infusion period =-9= Placeto-Cohot 1 ge isteroxime0.S us/Ke/min cTnT — 0 to 24 hours o 3 6 § 2 wa wm Heart Rate istaroxime 1.0 pg/kg/min vs. placebo 9 : Infusi
Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Clinically Significant Arrhythmias Clinically Significant Arrhythmias 12.0% 10.5% 10.5% 10.5% 25.0% 2o0% 200% 200% 100% - 30% 15.0% 25% 50% jo0% jo0% 100% 7 28% 28% 28% ee | a | oo oo% oo% Bas
Slide 15: Istaroxime — Acute Heart Failure Next Steps
Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact
Slide 16: Istaroxime Early Cardiogenic Shock
Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development
Slide 17: Cardiogenic Shock
Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf
Slide 18: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrythmias, decreasing blood pressure, renal dysfunction and
Slide 19: Changes in SBP — Phase 2a and 2b Dose Groups
Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change 0.5 pg/kg/min 1.0 g/kg/min 1.5 pg/kg/min Study/Dose Mean SBP at Baseline “112 mmHg m6 Hours m 24 H
Slide 20: Istaroxime Early Cardiogenic Shock Study
Istaroxime Early Cardiogenic Shock Study Ongoing early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure S E70 ~60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF in the EU and US 1.0 - 1.5ug/kg/min targ
Slide 21: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation Istarox
Slide 22: Summary: Potential to Create Value
Summary Potential to Create Value Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in phase 2 or phase 3 development for AHF treatment Istaroxime — dual-mechanism therapy with positive phase 2a and 2b trial outcomes: v Improved cardiac function
Slide 23: Lyo Lucinactant
Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients
Slide 24: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function
COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses angiotensin- ACE2 is surface molecule on converting enzyme 2 alveolar Type 2 lung cells — inflated and for proper gas exchange; (ACE2) for entry into host the source of surfactant Type 2 cell damage results
Slide 25: Surfactant Administration in Severe COVID-19 Lung Injury
Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits j . = Synthetic KL4 surfactant may mitigate surfactant deficiency Be ee] and resist widespread surfactant destruction that can . occur as a result of COVID-19 = Synthetic KL4 surfactant remove
Slide 26: Phase 2 Study of Lucinactant for Treatment of COVID-19
Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS ¢ Up to 20 patients from 4-5 US sites and up to 4 sites in Latin America FF
Slide 27: AEROSURF
AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)
Slide 28: Respiratory Distress Syndrome (RDS) Current Treatment Pathways
Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli
Slide 29: AEROSURF - Potential to Impact the Clinical Course of RDS
AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Respiratory Parameters Long-Term Outcomes Study results show evidence of potential impact on clinical course of RDS and respiratory health of preterm infan
Slide 30: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach (1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: * Demonstrate that new ADS works and supplement phase 2 data * Optimize dosing with more drug and shorter repeat intervals v Transition
Slide 31: Financial Summary & Capitalization as of June 30, 2021
Financial Summary & Capitalization as of June 30, 2021 = Cash & Equivalents of ~$30.0 million re Common Equivalents Securities q as of June 30, 2021 Common Stock 26,704,456 Options (WAEP $11.30) 3,266,141 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 46,599,399 SQ winotREe @ vrewarcurie
Slide 32: Strategy for Value Generation
Strategy for Value Generation Se we WINDTREE THERAPEUTICS. G Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts (Of Transactions: * Secure focused BD transactions for deal revenue and
Slide 33: Windtree Therapeutics
Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” Se wINDTREE we
Slide 34: Appendix
Appendix
Slide 35: Acute Heart Failure
Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state
Slide 36: Istaroxime Phase 2a (HORIZON-HF) Study
R é = Multicenter, double blind, placebo- controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% © SBP 90-150 mmHg = N=120 (30/group) = Significant improvement in PCWP, SBP, heart rate was lower. Ist
Slide 37: Istaroxime Phase 2b Adverse Events
Istaroxime Phase 2b Adverse Events Pooled placebo (n=39) istaroxime 0.5 me/Ke/min (n=41) istaroxime 1.0 Alladverse events Adverse events leading to discontinuation Serious adverse events 2 (5.1%) Cardiac death - Cardiogenic shock z 23 (59.0%) 1 (2.6%) Cardiac failure 1 (2.6%) Renal embolism = Transi
Slide 38: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study
KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur
Slide 39: Evidence of KL4 Surfactant Potential Utility in COVID-19
Evidence of KL4 Surfactant Potential Utility in COVID- Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicabi of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic Demons tility of Extensive St
Slide 40: Respiratory Distress Syndrome (RDS) Current Treatment Pathways
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf
Slide 41: Windtree Technology Platform — AEROSURF
Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ability to aerosolize KLa surfactant for RDS approved by the FDA Lyo
Slide 42: Transformative Potential of AEROSURF
Transformative Potential of AEROSURF® Surfactant Therapy Reversing surfactant deficiency hasa profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement es BPD Infection, ventilator-induced pneumonia RISKS cord damage, asthma, lung damage nCPAP Respirator
Slide 43: Business Development Focus
Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia wider Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out-Li
Windtree Therapeutics — Investor Presentation (September 2021) on 6ix